TESARO, Inc. (NASDAQ:TSRO) – Equities research analysts at SunTrust Banks reduced their FY2020 earnings estimates for shares of TESARO in a research report issued on Tuesday. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will earn $6.84 per share for the year, down from their prior forecast of $7.20.

TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.52) by $0.30. TESARO had a negative return on equity of 97.17% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the previous year, the company earned ($1.28) EPS. The business’s revenue for the quarter was down 17.6% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: “TESARO, Inc. (TSRO) to Post FY2020 Earnings of $6.84 Per Share, SunTrust Banks Forecasts” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/10/tesaro-inc-tsro-to-post-fy2020-earnings-of-6-84-per-share-suntrust-banks-forecasts.html.

TSRO has been the topic of a number of other research reports. Piper Jaffray Companies started coverage on shares of TESARO in a report on Wednesday, April 12th. They set an “overweight” rating and a $180.00 target price on the stock. Gabelli started coverage on shares of TESARO in a report on Friday, July 7th. They set a “buy” rating and a $175.00 target price on the stock. Oppenheimer Holdings, Inc. started coverage on shares of TESARO in a report on Thursday, May 25th. They set an “outperform” rating and a $183.00 target price on the stock. Wedbush raised shares of TESARO to an “outperform” rating and set a $168.00 target price on the stock in a report on Monday, June 5th. Finally, ValuEngine raised shares of TESARO from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $176.35.

Shares of TESARO (TSRO) traded down 5.04% on Thursday, hitting $110.32. 542,811 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $132.43 and its 200 day moving average is $149.67. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The firm’s market cap is $5.96 billion.

In other news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 40.50% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. FMR LLC boosted its stake in shares of TESARO by 0.4% in the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock worth $1,237,718,000 after buying an additional 32,918 shares during the period. BlackRock Inc. boosted its stake in shares of TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after buying an additional 3,335,611 shares during the period. Vanguard Group Inc. boosted its stake in shares of TESARO by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock worth $448,705,000 after buying an additional 103,759 shares during the period. State Street Corp boosted its stake in shares of TESARO by 0.4% in the first quarter. State Street Corp now owns 991,856 shares of the biopharmaceutical company’s stock worth $152,617,000 after buying an additional 3,784 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of TESARO by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 703,774 shares of the biopharmaceutical company’s stock worth $98,430,000 after buying an additional 28,177 shares during the period.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.